| abstract |
An effective amount of an antagonist that binds to a B-cell surface marker is administered to a patient eligible for treatment, thereby significantly improving at least two of dryness, fatigue, and joint pain in comparison to the baseline level in the visual analogue grade. How to treat Sjogren's syndrome in eligible patients; And articles of manufacture therefor. Sjogren in a subject eligible for treatment comprising administering to a subject eligible for treatment an effective amount of an antibody that binds a B-cell surface marker to provide initial and subsequent exposure to the antibody within a specific dosing regimen. How to treat the syndrome; And articles of manufacture thereof are also provided.n n n Sjogren's syndrome, visual analogue grade (VAS), dryness, fatigue, joint pain, CD20 antibody, antimalarial |